פינלנד - פינית - Fimea (Suomen lääkevirasto)

alfred e.tiefenbacher gmbh & co. kg - galantamini hydrobromidum - tabletti, kalvopäällysteinen - 4 mg - galantamiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

alfred e.tiefenbacher gmbh & co. kg - galantamini hydrobromidum - tabletti, kalvopäällysteinen - 8 mg - galantamiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

alfred e.tiefenbacher gmbh & co. kg - galantamini hydrobromidum - tabletti, kalvopäällysteinen - 12 mg - galantamiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

medice arzneimittel pÜtter gmbh & co. kg - dexamphetamine sulphate - tabletti - 5 mg - deksamfetamiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

medice arzneimittel pÜtter gmbh & co. kg - dexamphetamine sulphate - tabletti - 10 mg - deksamfetamiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

medice arzneimittel pÜtter gmbh & co. kg - dexamphetamine sulphate - tabletti - 20 mg - deksamfetamiini

האיחוד האירופי - פינית - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressantit - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

האיחוד האירופי - פינית - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - niveltulehdus, nivelreuma - immunosuppressantit - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

פינלנד - פינית - Fimea (Suomen lääkevirasto)

parke davis & co. ltd. - methylpolysiloxan,liuosta varten-geeli. haihtua,magnesiumia varten - tabletti - antasideja ja kaasunmuodostusta vähentäviä lääkeaineita sisältävät yhdistelmävalmisteet

האיחוד האירופי - פינית - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migreenihäiriöt - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.